Market Overview:
The global monoclonal antibody for multiple myeloma market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of multiple myeloma, rising awareness about monoclonal antibodies for the treatment of multiple myeloma, and technological advancements in the field of monoclonal antibody therapy. The global monoclonal antibody for multiple myeloma market can be segmented on the basis of type into elotuzumab, daratumumab, siltuximab, dacetuzumab, rituximab and other types. On the basis of application, this market can be segmented into hospitals, drug centers clinics and other applications. Geographically speaking, this market is segmented into North America Latin America Europe Asia Pacific and Middle East & Africa.
Product Definition:
A monoclonal antibody is a protein that has been designed in the laboratory to specifically bind to a single target molecule. Monoclonal antibodies are used in the diagnosis and treatment of cancer and other diseases.
Elotuzumab:
Elotuzumab is a Monoclonal Antibody (MAB) that targets and inhibits the tumor-associated macrophage colony-stimulating factor. It was approved by the FDA in 2011 for treatment of relapsed or refractory Diffuse Large B-cell Lymphoma, which is associated with MCL (Middle Cerebral Artery), as well as for patients who are experiencing stroke or TIA (Transient Ischemic Attack).
Daratumumab:
Daratumumab is a monoclonal antibody that targets and inhibits the activity of BCR-ABL1, an oncogene involved in myeloma. It has been approved by the FDA for use in patients with relapsed or refractory (R/R) multiple myeloma who are undergoing treatment with at least one immunomodulating drug.
Application Insights:
The hospital application segment dominated the global market in 2017. Monoclonal antibodies for multiple myeloma are primarily used in the treatment of patients with refractory or relapsed disease after ATN therapy. The availability of different therapeutic options, such as immunomodulatory drugs and biologics, has led to a higher adoption rate of monoclonal antibody therapies among hospitals across the globe.
Moreover, increasing awareness about these therapies and their benefits is further expected to drive demand from this segment over the forecast period. For instance, in January 2018 European Organization for Research and Treatment of Cancer (EORTC) released new guidelines regarding rituximab use that mentioned its benefits including reduced adverse effects when compared with other options like chemotherapy or radiation therapy. This factor is anticipated to boost overall revenue generation from this segment over the forecast period by way of contributing toward higher adoption rates globally among hospitals and healthcare centers.
Regional Analysis:
North America dominated the global monoclonal antibody for multiple myeloma market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; F. Hoffmann-La Roche AG; and Celgene Corporation, headquartered in this region along with increased research activities by various companies. Moreover, increasing incidence of cancer is also one of the major factors responsible for its largest share. According to NCI, around 14 million people are diagnosed with cancer every year and more than 7 million people die due to it in North America alone which is a huge number that needs treatment & diagnosis options available during their lifetime period (prevention or cure).
Growth Factors:
- Increasing incidence of multiple myeloma
- Rising demand for monoclonal antibody therapies
- Growing awareness about multiple myeloma and its treatment options
- Technological advancements in monoclonal antibody therapy development
- Availability of government funding for monoclonal antibody therapy research
Scope Of The Report
Report Attributes
Report Details
Report Title
Monoclonal Antibody for Multiple Myeloma Market Research Report
By Type
Elotuzumab, Daratumumab, Siltuximab, Dacetuzumab, Rituximab, Other
By Application
Hospital, Drug Center, Clinic, Other
By Companies
Bristol Myers Squibb, Abbvie, Janssen Biotech, Karyopharm Therapeutics, PDL BioPharma, Roche, Seattle Genetics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Monoclonal Antibody for Multiple Myeloma Market Report Segments:
The global Monoclonal Antibody for Multiple Myeloma market is segmented on the basis of:
Types
Elotuzumab, Daratumumab, Siltuximab, Dacetuzumab, Rituximab, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Center, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb
- Abbvie
- Janssen Biotech
- Karyopharm Therapeutics
- PDL BioPharma
- Roche
- Seattle Genetics
Highlights of The Monoclonal Antibody for Multiple Myeloma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Elotuzumab
- Daratumumab
- Siltuximab
- Dacetuzumab
- Rituximab
- Other
- By Application:
- Hospital
- Drug Center
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Monoclonal Antibody for Multiple Myeloma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Monoclonal antibody therapy is a type of cancer treatment that uses antibodies to target and destroy cancer cells. Monoclonal antibodies are made from one type of immune cell, called a monocyte, which is isolated from the blood of someone who has never had cancer. These antibodies are then injected into the patient's bloodstream or spinal cord.nnThe monoclonal antibody therapy used to treat multiple myeloma targets the protein B-cell lymphoma 2 (BCL2), which is often found in tumors associated with multiple myeloma. This therapy can help shrink or even eliminate tumors in some patients, although it does not always work and may have side effects.
Some of the key players operating in the monoclonal antibody for multiple myeloma market are Bristol Myers Squibb, Abbvie, Janssen Biotech, Karyopharm Therapeutics, PDL BioPharma, Roche, Seattle Genetics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Monoclonal Antibody for Multiple Myeloma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Monoclonal Antibody for Multiple Myeloma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Monoclonal Antibody for Multiple Myeloma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Monoclonal Antibody for Multiple Myeloma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Monoclonal Antibody for Multiple Myeloma Market Size & Forecast, 2018-2028
4.5.1 Monoclonal Antibody for Multiple Myeloma Market Size and Y-o-Y Growth
4.5.2 Monoclonal Antibody for Multiple Myeloma Market Absolute $ Opportunity
Chapter 5 Global Monoclonal Antibody for Multiple Myeloma Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type
5.2.1 Elotuzumab
5.2.2 Daratumumab
5.2.3 Siltuximab
5.2.4 Dacetuzumab
5.2.5 Rituximab
5.2.6 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Monoclonal Antibody for Multiple Myeloma Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Center
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Monoclonal Antibody for Multiple Myeloma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Monoclonal Antibody for Multiple Myeloma Analysis and Forecast
9.1 Introduction
9.2 North America Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type
9.6.1 Elotuzumab
9.6.2 Daratumumab
9.6.3 Siltuximab
9.6.4 Dacetuzumab
9.6.5 Rituximab
9.6.6 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Center
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Monoclonal Antibody for Multiple Myeloma Analysis and Forecast
10.1 Introduction
10.2 Europe Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type
10.6.1 Elotuzumab
10.6.2 Daratumumab
10.6.3 Siltuximab
10.6.4 Dacetuzumab
10.6.5 Rituximab
10.6.6 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Center
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Monoclonal Antibody for Multiple Myeloma Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type
11.6.1 Elotuzumab
11.6.2 Daratumumab
11.6.3 Siltuximab
11.6.4 Dacetuzumab
11.6.5 Rituximab
11.6.6 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Center
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Monoclonal Antibody for Multiple Myeloma Analysis and Forecast
12.1 Introduction
12.2 Latin America Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type
12.6.1 Elotuzumab
12.6.2 Daratumumab
12.6.3 Siltuximab
12.6.4 Dacetuzumab
12.6.5 Rituximab
12.6.6 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Center
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Monoclonal Antibody for Multiple Myeloma Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Type
13.6.1 Elotuzumab
13.6.2 Daratumumab
13.6.3 Siltuximab
13.6.4 Dacetuzumab
13.6.5 Rituximab
13.6.6 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Monoclonal Antibody for Multiple Myeloma Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Center
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Monoclonal Antibody for Multiple Myeloma Market: Competitive Dashboard
14.2 Global Monoclonal Antibody for Multiple Myeloma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol Myers Squibb
14.3.2 Abbvie
14.3.3 Janssen Biotech
14.3.4 Karyopharm Therapeutics
14.3.5 PDL BioPharma
14.3.6 Roche
14.3.7 Seattle Genetics
